Aligos Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address significant unmet medical needs in viral and liver diseases. The company's purpose-built pipeline targets chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses. Key clinical assets include pevifoscorvir sodium (ALG-000184), a capsid assembly modulator in Phase 2 development for chronic HBV; ALG-055009, an oral thyroid hormone receptor beta (THR-β) agonist in Phase 2a development for MASH; and ALG-097558, a pan-coronavirus protease inhibitor.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Shifting strategic focus and resources toward the clinical advancement of lead candidates ALG-055009 (for MASH) and pevifoscorvir sodium (ALG-000184, for chronic HBV) to maximize shareholder value.
Expected impact: Aims to transition Aligos from an early-stage R&D entity into a late-stage clinical powerhouse.
Focusing on clinical proof-of-concept before seeking regional or global strategic partnerships for late-stage clinical development and commercialization.
Expected impact: Extends cash runway and mitigates late-stage development risks while retaining global upside.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Amoytop exclusive rights to develop and commercialize pevifoscorvir sodium in Greater China, leveraging Amoytop's established hepatology presence.
Terms: Aligos received a $25 million upfront payment and is eligible for up to $420 million in development, regulatory, and sales milestones, plus tiered high single-digit royalties.